Receive The Newest Study Notifications

Clinical Trial Patient Recruitment Agency, Clinical Trial Media, Shares 4 Tips to Assist with Clinical Trial Advertisement

by Lance Smith | May 25, 2019 | Study Scavenger Clinical Trial Recruitment Platform

When advertising for clinical trials, you want to think of fresh and unique ways to capture potential patient’s attention and persuade them to get involved, all while adhering to federal guidelines. While this may sound like a complex advertising campaign,...

UCSF Doses First Patient in Triple Combination Clinical Trial of OncoSec’s TAVO™, Epacadostat and KEYTRUDA® for the Treatment of Unresectable Squamous Cell Head and Neck Cancer

by Lance Smith | May 25, 2019 | Study Scavenger Clinical Trial Recruitment Platform

First-of-its-kind study seeking to evaluate the potential anti-tumor effect of the IL-12, IDO1 and anti-PD-1 triple combination OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a late-stage cancer biotechnology company developing intratumoral gene-delivery...

Ascentage Pharma to Present New Data at 2019 ASCO Annual Meeting from Clinical Trials of MDM2-p53 Antagonist and IAP Inhibitor in Cancers

by Lance Smith | May 25, 2019 | Study Scavenger Clinical Trial Recruitment Platform

Ascentage Pharma, a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, hepatitis B virus and age-related diseases, today announced the presentation of new clinical data for its investigational apoptosis-targeted...

Targeting the CD47-SIRPA Axis in Oncology Analytical Tool – Early Technologies and Startups, Emerging Clinical Trial Results, Drug Approvals and the Ever-Changing Competitive Landscape

by Lance Smith | May 25, 2019 | Study Scavenger Clinical Trial Recruitment Platform

The “Targeting the CD47-SIRPA Axis in Oncology: Analytical Tool” report has been added to ResearchAndMarkets.com’soffering. Targeting the CD47-SIRPa axis is emerging as one of the most promising new cancer immunotherapy approaches seeking to target...

NeoImmuneTech Announces that the FDA has Allowed the Center for Cancer Research, National Cancer Institute to Proceed with an Investigational New Drug Application to Initiate a Clinical Trial for Hyleukin-7™ with Vaccines in Elderly Cancer Survivors

by Lance Smith | May 25, 2019 | Study Scavenger Clinical Trial Recruitment Platform

NeoImmuneTech, Inc. (NIT), a T cell-focused immunotherapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has allowed the Center for Cancer Research, National Cancer Institute to proceed with an Investigational New Drug application (IND)...

New York City Icahn School of Medicine at Mount Sinai and Renowned Global Researcher Dr. Hurd, Select MediPharm Labs to Support 500 Patient Major Clinical Study And “CBD International Consortium” to Develop Treatment of Opioid Addiction

by Lance Smith | May 25, 2019 | Study Scavenger Clinical Trial Recruitment Platform

MediPharm Labs enters major U.S. led opioid clinical research trial to develop IP and exclusively manufacture CBD gelcaps MediPharm Labs Corp. (TSXV: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs”) a leader in specialized, research-driven cannabis extraction and...